- $182.21bn
- $227.49bn
- $36.75bn
China's Harbour BioMed to focus on another patent case after $20 million damages award
Amgen owes $20.2 million in antibody patent lawsuit, US jury says (updated)
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen taps research firm to reassess Tavneos data (updated)
Brief: EMA's PRAC Agrees On DHPC For Tavneos On Reinforced Liver Monitoring Requirements
Amgen taps research firm to reassess Tavneos data
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Bristol Myers drug delays myeloma progression in hard to treat patients
Brief: Ember Lifesciences Announces New Strategic Investments Boosting Series A To $27 Million
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Honeywell quantum IPO tests financial paradox
Amgen says CFO Peter Griffith to retire, names Dittrich as successor (updated)
Amgen says CFO Peter Griffith to retire, names Dittrich as successor
Advisory: Incorrectly tagged Kissei alert withdrawn
Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports (updated)
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports
Brief: 20 People In Japan Who Took Amgen's Tavneos Have Died, And At Least 22 Developed A Potentially Fatal Liver Injury, As Per Kissei Pharmaceutical- WSJ